Vanguard Global Advisers’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
Other funds holding ACAD
BBA
Vanguard Global Advisers's ACAD Position: Q3 2026 in Review
Vanguard Global Advisers increased its Acadia Pharmaceuticals (ACAD) stake by 5% in Q3 2026, buying an estimated $64.4K and bringing the position to 50,355 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #1700.
Vanguard Global Advisers first reported a position in ACAD in Q1 2026 and has held it in 3 quarters since. The position peaked at $1.21M in Q2 2026. 346 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.
- Vanguard Global Advisers held 50,355 shares of Acadia Pharmaceuticals worth $1.01M as of Q3 2026.
- Vanguard Global Advisers bought 2,398 Acadia Pharmaceuticals shares in Q3 2026, an estimated $64.4K.
- Acadia Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #1700 holding.
- Vanguard Global Advisers first reported a position in Acadia Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
- Vanguard Global Advisers's Acadia Pharmaceuticals position peaked at $1.21M in Q2 2026.
- 346 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.
Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.